The Neutrino Donut is working with a company to develop their SBIR grant. We will be identifying opportunities, working with industry partners, and managing the development of the grant.
The Neutrino Donut is working on a project relating to develop a grant strategy program for a company developing medical software.
The Neutrino Donut has started advising multiple companies on the development of their grant programs. This is a six month consulting engagement and will involve identification of market development strategies and commercialization plans.
NIH SBIR/STTR Niche Assessment Program (NAP), I-Corps at NIH, and NIH SBIR/STTR Commercialization Accelerator Program (CAP).
A cornerstone of the SBIR and STTR programs is helping companies move along the path of commercialization, with an emphasis on reducing technology risk and increasing the value proposition. HHS offers the I-Corps TM at NIH program and the Niche Assessment Program for Phase I awardees, and the Commercialization Accelerator Program (CAP) for Phase II awardees.
Technologies supported by these programs include a range of drug, device, diagnostic or behavioral interventions.
The Commercialization Accelerator Program (CAP) assists small companies with getting their SBIR/STTR-developed technologies more rapidly into the marketplace. It provides assistance with developing and implementing an appropriate business strategy aimed at commercializing the products or services that have resulted from HHS-supported SBIR/STTR awards.
CAP can include distinctive tracks that offer customized assistance to meet the specific needs of both early stage and seasoned companies: 1) Commercialization Transition Track (CTT), 2) Advanced Commercialization Track (ACT), and 3) Regulatory Training track (RTT).
The CTT is suitable and relevant for the majority of HHS SBIR/STTR Phase II companies. In this track, participants will receive the tools to understand and put into practice the commercialization plans and activities critical to your company’s stage, level, and background. It also provides you with the opportunity to receive direct industry feedback in a live (in-person) session.
The ACT is suitable and relevant to companies that have some history of accomplishment in commercializing products and/or services, generating and maintaining revenue streams, or servicing a well-defined and steady customer base, and that have established partnerships. In this track, participants will focus on addressing a specific “gap” or applicable issue, which resolution is crucial for your continued progress and development. These issues may include (provided as examples only): Financial Issues and Valuation (financial modeling, budget analysis), Intellectual Property (license-focused IP strategy, refresh of patent portfolio), Market Strategy (related to a specific customer or opportunity), Marketing/Branding (marketing materials, branding/website), and Strategic Partnering (investor/go to market presentation, term sheet for investor/partnership).
This is where grant applicants have problems. They do not understand the process of taking their science into the marketplace. Issues such as product definition, pricing, scaling, customer identification, sales process, all are key topics for consideration. This is also where grant applications fail.
Contact us, we can help.
e hager 81 at gmail
The Neutrino Donut will be on two grant review panels later this fall, one for NIH and one for DoD. We will be reviewing the grants for commercialization opportunities.
The Neutrino Donut is working with NIH grant recipients on the development of their companies and technologies.
The Neutrino Donut is working with DoE grant recipients on the development of their companies and technologies.
The Neutrino Donut is consulting with an advanced materials startup. The company is managing licensing issues, fundraising via VC processes, grant processes, and business development.